Annexin A2 and tissue plasminogen activator for treating vascular disease
AssigneeThe General Hospital Corporation
InventorsXiaoying Wang, Eng Lo
Life of this patent
Estimating the term…
Abstract
The use of tPA to treat hemorrhagic transformation, neurotoxicity has been limited to short treatment time windows because a high dose of tPA required to generate sufficient amounts of the enzyme plasmin for clot lysis. The present invention combines tPA with recombinant Annexin A2 resulting in thrombolysis without hemorrhagic transformation at delayed times after stroke. This embodiment allows the administration of a lower, non-neurotoxic, tPA dose. Our results suggest this novel combination for stroke therapy may greatly improve both efficacy and safety, and prolong tPA therapeutic time window.
Claims20
A method comprising:
- a) providing:
- i) a patient exhibiting at least one fibrin clot associated with a vascular disorder, and
- ii) a medium comprising Annexin A2 and tissue plasminogen activator (tPA);
- b) administering said medium to said patient under conditions such that lysis of said at least one fibrin clot is increased, wherein said at least one fibrin clot is reduced in size by at least 80% in fifteen minutes.
A method comprising:
- a) providing:
- i) a human patient exhibiting at least one fibrin clot associated with a recently incurred stroke,
- ii) a medium comprising Annexin A2 and tissue plasminogen activator (tPA), wherein said Annexin A2 and said tPA have a dose ratio of 2:1;
- and,
- b) administering said medium to said human patient under conditions such that lysis of said at least one fibrin clot is increased.
Dependencies are inferred from the claim text.